Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1996 Mar;80(3):200–202. doi: 10.1136/bjo.80.3.200

Activated protein C resistance in young adults with central retinal vein occlusion.

J Larsson 1, E Olafsdottir 1, B Bauer 1
PMCID: PMC505428  PMID: 8703855

Abstract

BACKGROUND: Central retinal vein occlusion is a disease that is most common in old people. While the disease in old people often is associated with atherosclerosis, hypertension, diabetes, or glaucoma, this is much less evident in young people. However, a new defect in the anticoagulant system has recently been discovered, activated protein C resistance. This hereditary defect may well be associated with central retinal vein occlusion, and so this factor was analysed in patients younger than 50 years with a history of central retinal vein occlusion. METHODS: Blood samples were obtained from 31 patients younger than 50 years with a history of central retinal vein occlusion, and analysed for activated protein C resistance with standard clinical laboratory methods. RESULTS: In this material 26% of all the patients and 36% of the patients younger than 45 years were resistant to activated protein C. The normal incidence of activated protein C resistance is 2-7%. CONCLUSION: Activated protein C resistance seems to be the most common known cause of central retinal vein occlusion in young people.

Full text

PDF
200

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dahlbäck B., Carlsson M., Svensson P. J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1004–1008. doi: 10.1073/pnas.90.3.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dahlbäck B., Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1396–1400. doi: 10.1073/pnas.91.4.1396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dahlbäck B., Svensson P. J. Nyupptckt rubbning i antikoagulationen. Resistens mot aktiverat protein C orsak till trombos. Lakartidningen. 1994 Jan 5;91(1-2):50–53. [PubMed] [Google Scholar]
  4. Davie E. W., Fujikawa K., Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991 Oct 29;30(43):10363–10370. doi: 10.1021/bi00107a001. [DOI] [PubMed] [Google Scholar]
  5. Fong A. C., Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol. 1993 May-Jun;37(6):393–417. doi: 10.1016/0039-6257(93)90138-w. [DOI] [PubMed] [Google Scholar]
  6. Greengard J. S., Sun X., Xu X., Fernandez J. A., Griffin J. H., Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 1994 May 28;343(8909):1361–1362. doi: 10.1016/s0140-6736(94)92497-x. [DOI] [PubMed] [Google Scholar]
  7. Koster T., Rosendaal F. R., de Ronde H., Briët E., Vandenbroucke J. P., Bertina R. M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993 Dec 18;342(8886-8887):1503–1506. doi: 10.1016/s0140-6736(05)80081-9. [DOI] [PubMed] [Google Scholar]
  8. Legnani C., Palareti G., Biagi R., Coccheri S. Activated protein C resistance in deep-vein thrombosis. Lancet. 1994 Feb 26;343(8896):541–542. doi: 10.1016/s0140-6736(94)91494-x. [DOI] [PubMed] [Google Scholar]
  9. Lindblad B., Svensson P. J., Dahlbäck B. Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C. Lancet. 1994 Apr 9;343(8902):917–917. doi: 10.1016/s0140-6736(94)90035-3. [DOI] [PubMed] [Google Scholar]
  10. Malm J., Laurell M., Nilsson I. M., Dahlbäck B. Thromboembolic disease--critical evaluation of laboratory investigation. Thromb Haemost. 1992 Jul 6;68(1):7–13. [PubMed] [Google Scholar]
  11. McGrath M. A., Wechsler F., Hunyor A. B., Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med. 1978 Feb;138(2):216–220. [PubMed] [Google Scholar]
  12. Priluck I. A., Robertson D. M., Hollenhorst R. W. Long-term follow-up of occlusion of the central retinal vein in young adults. Am J Ophthalmol. 1980 Aug;90(2):190–202. doi: 10.1016/s0002-9394(14)74853-6. [DOI] [PubMed] [Google Scholar]
  13. Svensson P. J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994 Feb 24;330(8):517–522. doi: 10.1056/NEJM199402243300801. [DOI] [PubMed] [Google Scholar]
  14. Tabernero M. D., Tomas J. F., Alberca I., Orfao A., Lopez Borrasca A., Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol. 1991 Apr;36(4):249–254. doi: 10.1002/ajh.2830360405. [DOI] [PubMed] [Google Scholar]
  15. Walters R. F., Spalton D. J. Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients. Br J Ophthalmol. 1990 Jan;74(1):30–35. doi: 10.1136/bjo.74.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES